Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study.

MLA

Koutras, Angelos, et al. “Evaluation of the Prognostic Significance of HER Family MRNA Expression in High-Risk Early Breast Cancer: A Hellenic Cooperative Oncology Group (HeCOG) Validation Study.” Journal of Translational Medicine, vol. 13, May 2015, p. 171. EBSCOhost, https://doi.org/10.1186/s12967-015-0530-0.

APA

Koutras, A., Kalogeras, K. T., Wirtz, R. M., Alexopoulou, Z., Bobos, M., Zagouri, F., Veltrup, E., Timotheadou, E., Gogas, H., Pentheroudakis, G., Pisanidis, N., Magkou, C., Christodoulou, C., Bafaloukos, D., Papakostas, P., Aravantinos, G., Pectasides, D., Kalofonos, H. P., & Fountzilas, G. (2015). Evaluation of the prognostic significance of HER family mRNA expression in high-risk early breast cancer: a Hellenic Cooperative Oncology Group (HeCOG) validation study. Journal of Translational Medicine, 13, 171. https://doi.org/10.1186/s12967-015-0530-0

Chicago

Koutras, Angelos, Konstantine T Kalogeras, Ralph M Wirtz, Zoi Alexopoulou, Mattheos Bobos, Flora Zagouri, Elke Veltrup, et al. 2015. “Evaluation of the Prognostic Significance of HER Family MRNA Expression in High-Risk Early Breast Cancer: A Hellenic Cooperative Oncology Group (HeCOG) Validation Study.” Journal of Translational Medicine 13 (May): 171. doi:10.1186/s12967-015-0530-0.